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[57] ABSTRACT 
There is provided a novel derivative of 2-acetoxyben 
zoic acid, i.e., 1-O-(2'-acetoxy)benzoyl-a-D-2-deoxy 
glucopyranose, which is suitable for the attainment of 
high 2-acetoxybenzoic acid blood levels without irrita 
tion of the gastrointestinal lining. 
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DERIVATIVE 0F ASPIRIN 
BACKGROUND OF THE-‘INVENTION 
1. Field of the Invention . 
The present invention relates to 2-acetoxybenzoic 
acid and more particularly, the present invention relates 
to a therapeutically useful derivative of 2-acetoxyben 
zoic acid, i.e., l-O-(2’—acetoxy)benzoyl-a-D-2-deoxy 
_ glucopyranose. 
The novel compound of this invention exhibits anal 
gesic, antipyretic, and 'antirheumatic therapeutic activ 
ity. 
The compound, 2-acetoxybenzoic acid, is commonly 
known as “aspirin” and/ or “acetylsalicylic acid”, and is 
one of the most widely used compounds in the treat 
ment of simple pain and in?ammation. 2-Acetoxyben 
zoic acid is widely employed as an analgesic, an antipy 
retic, an anti-inflammatory and an antirheumatic agent, 
and it is particularly useful in the relief of fever, head 
ache, myalgia, arthralgia and other pains associated 
with integumental structures. 2-Acetoxybenzoic acid is 
generally administered for these conditions in the form 
of a powder, particle, capsule, solution, tablet or other 
pharmaceutically acceptable dosage form because it is 
advantageous from the standpoint that chronic use of 
the compound will not lead to a tolerance of addiction 
thereof. Moreover, its toxicity is much lower than most 
compounds possessing similar pharmacologic activity. 
However, 2-acetoxybenzoic acid, as'used for these pur 
poses, is well-known by the practicing skilled artisan of 
the medical arts to exhibit certain unwanted and 
deliterious side effects'?Speci?cally, it induces occult 
hemorrhaging in the gastrointestinal tract, which ‘results 
from contact of the insoluble solid particulate of the 
compound with the gastrointestinal mucosa. As a result 
of this insolubilization, the very acidic particles of 2 
acetoxybenzoic acid will adhere to the gastrointestinal 
mucosa in the form of crystals and such crystals, taken 
together with the acidic environment of the gastrointes 
tinal lining, will produce microetching thereof, which 
in turn, leads to gastrointestinal bleeding. ' 
2. Description of the Prior Art . 
To date, it is known that gastric bleeding can be 
diminished if (1) an aqueous solution of 2-acetoxyben 
zoic acid is administered, or (2) a buffered aqueous 
solution of 2-acetoxybenzoic acid is administered. How 
ever, such solutions leave much to be desired in that 
they are commercially and consumerwise unacceptable, 
i.e., water and/ or buffered solutions are unacceptable as 
a suitable pharmaceutical‘dosage form. _ 
One product on the market, commercially known as 
“Alka-Seltzer ®" is basically an alkaline effervescent 
2-acetoxybenzoic‘acid formulation, which, does exhibit 
satisfactory water'solubility and dissolution, insofar as 
2-acetoxybenzoic acid is concerned. However, at least 
three disadvantages are associated with this product. 
Firstly, the product is contained in a tablet 'form and 
must initially be dissolved in water prior to consump 
tion. Secondly, because ‘the product contains a high 
amount of sodium ion, it is unacceptable for administra 
tion to hypertensive patientstthose who suffer from 
high blood pressure), because it has now beenmedically 
established that the sodium ion contributes to hyperten 
sion. Thirdly, the alkaline nature of the product per se 
alters the pH of the blood and urine. to the alkaline side. 
Chronic use of this product could thus initiate alkalosis. 
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It has also been proposed to avoid the adverse effects 
of Z-acetoxybenzoic acid by the use of various esteri?ed 
derivatives thereof, wherein transient blocking of the 
acidic carboxylic group'of aspirin occurs. For instance, 
French Patent No.’ Ml453'de'scribes various antipyretic 
and analgesic compounds formed by esterifying 2 
acetoxybenzoic acid with various sugars. Whether such 
derivatives are viable substitutes for Z-acetoxybenzoic 
acid depends not only upon whether these derivatives 
have therapeutic value per se, but to a larger extent 
upon whether these derivatives have the potential to 
revert to 2-acetoxybenzoic acid by hydrolysis in vivo. 
In this regard, it is notable that certain derivatives of 
2-acetoxybenzoic acid tend to hydrolyze so as to form 
the corresponding ester of salicylic acid and not aspirin. 
The following reaction scheme serves to illustrate the 
manner in which derivatives of 2-acetoxybenzoic acid 
may hydrolyze: ‘ 
II II 
c-o-n c-o-n 
Z-Acetoxybenzoic Acid Ester 
\l/ (11) 
Z-Acetoxybenzoic Acid 
Salicylic Acid Ester 
It is apparent that only those esteri?ed derivatives of 
Z-acetoxybenzoic acid which hydrolyze according to 
reaction scheme (I), so as to produce aspirin, are viable 
substitutes for aspirin. Also, such a substitute must hy 
drolyze at a rate sufficient to release aspirin in therapeu 
tically effective quantities. 
It has recently been discovered that the aspirin deriv 
ative, l-O-(2’-acetoxy)benzoyl-a-D-glucopyranose, 
tends to hydrolyze so as to form the corresponding 
sugar derivative of salicylic acid, as per reaction scheme 
(II) depicted above. Furthermore, to the extent that 
hydrolysis to aspirin takes place, such hydrolysis takes _ 
place only at a very slow rate. 
In summary, the various prior art sugar derivatives of 
2-acetoxybenzoic acid present a non-irritating neutral 
molecule to the gastrointestinal lining when adminis 
tered for therapeutic purposes. However, the group 
which blocks the carboxylic acid function of Z-acetox 
ybenzoic acid tends to be bound thereto very tightly. 
Such prior art derivatives, therefore, do not release 
aspirin in vivo in therapeutically sufficient quantities. 
Thus, a need exists for a Z-acetoxybenzoic acid deriva 
tive, wherein transient blocking of the carboxylic func 
tion occurs, yet wherein the blocking group is not so 
tenaciously bound thereto. 
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SUMMARY OF THE INVENTION 
Accordingly, it is one object of the present invention 
to provide a derivative of Z-acetoxybenzoic acid which 
does not tend to cause local irritation of the gastrointes- 5 
tinal tract, yet which is capable of hydrolyzing at a rate 
sufficient to release 2-acetoxybenzoic acid in vivo in 
therapeutically sufficient quantities. 
It is another object of the present invention to pro 
vide a derivative of 2-acetoxybenzoic acid which will 10 
permit a therapeutically effective compound to be ab 
sorbed through the gastrointestinal lining, in a manner 
such that insoluble, acidic particles of 2-acetoxybenzoic 
acid are not contacted therewith, thus eliminating gas 
trointestinal bleeding. 
Finally, it is yet another object of the present inven 
tion, to provide a derivative of 2-acetoxybenz0ic acid, 
which can be formulated in a suitable oral pharmaceuti 
cally acceptable dosage form for administration as an 
analgesic, an antipyretic, an anti-in?ammatory and an 
antirheumatic agent to warm-blooded animals. 
These and other objects of the instant invention will 
become more readily apparent from a reading of the 
accompanying disclosure and appended claims thereto. 
The foregoing objects are attained with the use of a 
novel acylal derivative of 2-acetoxybenzoic acid, i.e., 
l-O-(2'-acetoxy)benzoyl-a-D-2-deoxyglucopyranose. 
The structure of this compound may be represented as 
follows: 
15 
25 
30 
H OH 
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O 35 
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DETAILED DESCRIPTION OF THE 40 
INVENTION 
l-O-(2’-acetoxy)benzoyl-a-D-Z-deoxyglucopyranose 
can be synthesized according to the following scheme: 
45 
OH 
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OH 
CI-h-O Ho 
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-continued 
(1]) GLACIAL ACETIC ACID 9 Ho 
2N H2504 HEAT 
0 
(HA) CHZOBZ 
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PRODUCT 
The above method is basically a modi?cation of the 
method reported by Glaudemans and Fletcher in Meth 
ods of Carbohydrate Chemistry. Vol. VI, R. L. Whistler 
and J. N. Bemiller, Eds., Academic Press, New York, 
New York (1972), pp. 373—376. 
Numerous modi?cations in the depicted reaction 
scheme will be apparent to those skilled in the art. For 
example, protecting groups other than benzyl can be 
employed, so long as they can be readily removed after ' 
coupling of the a-D-Z-deoxyglucopyranose and 2 
acetoxybenzoic acid portions of the molecule. Thus, 
p-methoxybenzyl or tert-butyl radicals could be intro 
duced into the glucopyranose molecule instead of the 
benzyl protecting groups. After coupling, benzyl and 
p-methoxybenzyl protecting groups can be conve 
niently removed by catalytic hydrogenolysis. Suitable 
catalysts may include rhodium, platinum, ruthenium, 
Raney nickel and palladium (optionally on a support), a 
particularly preferred catalyst being palladium-on-car 
bon. When protecting groups which are normally not 
sensitive to catalytic hydrogenolysis, e. g., tert-butyl 
radicals, are employed, removal may be effected by use 
of an acid such as tri?uoroacetic acid. 
Variations in the coupling reaction would also be 
possible. For example, the acid chloride starting mate 
rial could be reacted with the protected glucopyranose 
in the presence of suitable bases other than pyridine, 
e.g., other tertiary aliphatic or aromatic amines such as 
N-methylmorpholine, triethylamine, and picoline, con 
veniently in a non-protic solvent. Alternatively, the 
protected glucopyranose could be reacted with 2 
acetoxybenzoic acid (rather than with the acid chlo 
ride), in which case the reaction would be conducted in 
the presence of a suitable dehydrating agent, for exam 
ple, an aromatic or aliphatic carbodiimide. 
The invention will appear more fully from the exam‘ 
ples which follow. 
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' EXAMPLE 1 
Preparation , of l-O-methyl-a-D-Z-deoxyglucopyranose 
Fifteen grams (0.09 moles) of 2-deoxyglucose were 
dissolved in 540 milliliters of 2% methanolic hydrochlo 
ric acid and the solution was warmed to 40° C. in a 
water bath. The solution was shaken occasionally for 
one hour, then allowed to cool to room temperature and 
stirred with thirty-two grams of sodium carbonate for 
?fteen minutes. The solution was ?ltered and the ?ltrate 
was concentrated under diminished pressure to yield a 
light yellow oil containing a small amount of white 
solid. The oily mixture was then stirred vigorously with 
750 milliliters of acetone for thirty minutes. The result 
ing suspension was ?ltered and the ?ltrate was concen 
trated under diminished pressure to yield a clear light 
yellow oil. The oil was combined with ?ve milliliters of 
absolute ethanol and the mixture stored at —20° C. 
Large clear crystals of l-O-methyl-a-D-Z-deoxy 
glucopyranose separated spontaneously after two to 
three days. The crystalline material was recovered by 
?ltration and washed with cold (—20° C.) ethyl acetate. 
NMR (DMSO-d@): 84.1-4.8(m,3,—O—H),63 
.1-4.l(m,9,3—6 H's,l H, —OCI;I3), 81. l—2.3(m,2,2—H's). 
EXAMPLE 2 
Preparation of 
l-O-methyl-3,4,6-tri-O-benzyl-a-D-2-deoxy 
glucopyranose 
Nine grams (0.05 moles) of l-O-methyl-ot-D-Z-deoxy 
glucopyranose was added to a suspension of 44.8 grams 
of ?nely powdered potassium hydroxide in 110 milli 
liters of dry dioxane and the mixture was warmed to 
re?ux. When the reaction mixture was re?uxing 
smoothly, sixty-two milliliters of colorless benzyl chlo 
ride was added dropwise over a period of about forty 
?ve minutes. The mixture was re?uxed for an additional 
period of forty minutes, then cooled. The apparatus was 
rearranged and the dioxane was distilled off over a 
period of three hours. The residue was cooled, diluted 
with water to a total volume of 350 milliliters, and ex 
tracted successively with 300, 200, 100 and 100 milliliter 
portions of ether. The ether portions were combined 
and dried over anhydrous sodium sulfate, then were 
?ltered. Ether was removed from the ?ltrate under 
diminished pressure to yield a light yellow oil. The oily 
material was subjected to vacuum (10*4 mm Hg) distil 
lation with the bath temperature slowly increased to 
200° C. The product, an amber-colored oil, remained in 
the distillation pot in 96—l00% yield. NMR (CDC13); 
86.7—7.7(m,l5,ArI;I), 64.2-5.0(m,7,¢-C}_I2—O—- and 
l—H), ?3.4—4.2(m,5,3-through 6-glucose-H's), 
83.2(s,3,——OCI;I3), 8l.4—2.5 (m,2,2-position-H's). 
EXAMPLE 3 
Preparation of 
3,4,6-tri-O-benzyl-a-D-2-deoxyglucopyranose 
The amber oil obtained in Example 2 (22.3 grams, 
0.05 moles) was dissolved in 550 milliliters of hot (70° 
C.) glacial acetic acid, 240 milliliters of hot (70° C.) 
molar sulfuric acid were slowly added, and the, resulting 
mixture was maintained at 73°-75° C. for one hour. 
(The sulfuric acid was added slowly and with vigorous 
stirring to prevent precipitation of the starting mate 
rial.) The reaction mixture was then slowly added to 
three liters of vigorously stirred water. The mixture was 
stirred for two hours, then was kept at +10° C. for 
10 
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twenty-four hours. Filtration and washing with two 
sixty-milliliter portions of .methanol resulted in 14 grams 
(65% yield) of a white powder. Melting point: 96°—97° 
C. NMR (CDCl3): 86.7—7.7(m,15,ArI;I), 85.1-54 (broad 
s,l,1—H), 64.2—5.l(m,6,4>-CI;I2—O—), 83.2-4.2(m,6,3 
through 6-glucose-H's and l-OH), 61.4—2.5(m,2,2-posi 
tion). 
EXAMPLE 4 
Preparation of 
l-O-(2’-acetoxy)benzoyl-3,4,6-tri-O-benzyl-a-D-2 
deoxyglucopyranose. 
A solution of 13.7 grams (0.032 moles) of 3,4,6-tri-O 
benzyl-a-D-2—deoxyglucopyranose in 130 milliliters of 
dichloromethane was treated with a solution of 6.93 
grams (0.035 moles ) o-acetylsalicyloyl chloride and 2.8 
milliliters of dry pyridine in ?fty milliliters of dichloro 
methane and the resulting mixture was stirred at room 
temperature. After twenty-three hours, 100 grams of ice 
were added and stirring was continued for one hour. 
The bi-layered mixture was transferred to a separatory 
funnel and, the dichloromethane layer was washed suc 
cessively with water, 3 N sulfuric acid, water, and a 
saturated ‘aqueous solution of sodium bicarbonate. The 
dichloromethane layer was then dried over anhydrous 
sodium sulfate and ?ltered, and the ?ltrate was concen 
trated under diminished pressure to a clear oil in nearly 
quantitative yield. The oil, however, was found to con 
tain varying amounts of a second component. This ma 
terial was removed by dissolving the oily product in 200 
milliliters of methanol at room temperature and then 
cooling the resultant solution to —20° C. The desired 
product was isolated as a waxy solid by decanting the 
methanol layer. This procedure was repeated with 50 
milliliters of methanol, when necessary, to produce a 
unitary compound (TLC on silica gel with a mobile 
phase of chloroform/heptane/methanol/ formic acid at 
50/ 50/ 5/ l, Rf:0.57). The product was then isolated, in 
25% yield, as white, crystalline ?akes by recrystalliza 
tion from absolute ethanol (twenty milliliters per gram 
of product). NMR (CDC13): 66.7-8.0(m,l9,ArH), 
85.8(d, 1,1-H), 84.4-4.9(m,6, —-CI;l2—O—), 
83.4-3.9(m,5,3-through 6-position-H’s), 6l.0—2.5(m,5,2 
position and —OCOCI;I3). 
EXAMPLE 5 
, Preparation of 
l-O-(2'-acetoxy)benzoyl—a-D-2-deoxyglucopyranose 
One gram of l-O-(2’-acetoxy)benzoyl-3,4,6-tri-O-ben 
gyl-a-D-Z-deoxyglucopyranose was dissolved in 150 
milliliters of absolute ethanol in a Parr bottle and 0.6 
grams of 10% Pd/C was added. Hydrogenolysis at 60 
pounds per square inch of hydrogen pressure was car 
ried out for twelve hours. The reaction mixture was 
then ?ltered and the ?ltrate was concentrated under 
diminished pressure to a clear oil. The oil was washed 
with one ?fty-milliliter portion of petroleum ether. The 
product crystallized spontaneously in 95—l00% yields 
upon the addition of ?fteen milliliters of chloroform. 
NMR(acetone-d6): 87.0—8.2(m,4,ArH), 85.8-5.9(d,1,l 
H), 83.0-4.l(m8,3-through 6-H’s and —OH’s), 82.3(s,3, 
—OCOCI;I3), 81.0-2.3(m2,2-H’s). 
EXAMPLE 6 
At low pH, the absorbance spectrum of l-O-(2’ 
acetoxy)benzoyl-a-D-2-deoxyglucopyranose exhibits a 
large peak at 278 nanometers which is exactly like that 
4,242,330 
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observed for the unionized aspirin molecule. At a pH 
value of 6, the spectrum of the prodrug of the present 
invention remains unchanged, while that observed for 
the (ionized) aspirin molecule exhibits a signi?cant de 
crease in absorbance at wavelengths of 270 to 290 nano 
meters. Therefore, the decrease in absorbance of a solu 
tion containing both the prodrug of this invention and 
aspirin observed at 285 nanometers upon adjustment of 
the pH to a value of six is proportional to the amount of 
aspirin in the solution. 
Accordingly, the rate of generation of aspirin via 
hydrolysis of the derivative of the present invention 
was determined spectrophotometrically at 285 nm. So 
lutions of l-O-(2’-acetoxy)benzoylaa-D-2-deoxy 
glucopyranose in a buffered solution containing 5 
mg/ml were freshly prepared and maintained at con 
stant temperature in a circulating waterbath. An aliquot 
of 200 pl of the solution was added to 3 ml of buffered 
solution at pH 6 in a 1 cm path-length spectrophotome 
ter cell (Cary cell), and, after inverting several times to 
insure a uniform mixture, the absorbance versus a buff 
er-only blank was observed at 285 nm. Buffers em 
ployed were hydrochloric acid (pH 1 to 2), citrate (pl-I 
3), acetate (pH 4 to 6) and phosphate (pH 7-9). Ionic 
strength was adjusted with potassium chloride (usually 
to 0.1). The change in absorbance at 285 nm was fol 
lowed until no change in absorbance was observed. 
First order plots were constructed by plotting log 
(Ar-Aw) agains time. The effect of pH on the rate of 
hydrolysis was determined using solutions ranging from 
pH 1.2 to pH 9. 
The generation of aspirin from the derivative was 
found to be independent of the pH of the solutions as 
shown in the Table. The half-life for the hydrolysis at 
pH 3 and pH 8 at 37° C. was found to be 7 minutes. 
TABLE 
THE HALF-LIFE OF HYDROLYSIS OF l-O-(2" 
ACETOXY)BENZOYL-a-D-Z-DEOXYGLUCOPYRANOSE 
TO ASPIRIN AS A FUNCTION OF pH AT 37" C. 
pH tl/2‘(minutes) 
3 7 
4.6 7.1 
6.4 7.0 
s 1.02 
9 1.0 
‘Each half-life is the average of three determinations. 
Thus, the transient blocking of the acidic carboxylic 
group of aspirin by formation of an acylal-linked deriva 
tive results in a compound which regenerates aspirin at 
an acceptable rate. Such a compound reduces the gas 
trointestinal liability of aspirin by presenting a neutral 
molecule to the gastric membrane. 
EXAMPLE 7 
The rate of hydrolysis of l-O-(2'-acetoxy)benzoyl-a 
D-glucopyranose, i.e., the compound of the formula 
on 
3 OH 
c_o no 
0 
CHZOI-I 
was determined by following the rate of appearance of 
aspirin in a solution by high pressure liquid chromatog 
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raphy. l-O-(2’-acetoxy)benzoyl-a-D-glucopyranose 
was found to have a half-life of hydrolysis to aspirin of 
55 hours. 
The compound of this invention is conveniently ad 
ministered in oral dosage form, such as by tablet or 
capsule, by combining the same in a therapeutic amount 
(e.g., dosage regimen for aspirin on an equivalent 
weight basis) with any oral pharmaceutically accept 
able inert carrier, such as lactose, starch (pharmaceuti 
cal grade), dicalcium phosphate, calcium sulfate, kaolin, 
mannitol, and powdered sugar. In addition, when re 
quired, suitable binders, lubricants, disintegrating 
agents, and coloring agents can also be added. Typical 
binders include starch, gelatin, sugars, such as sucrose, 
molasses, and lactose, natural and synthetic gums such 
as acacia, sodium alginate, extract of Irish moss, carbox 
ymethylcellulose, methylcellulose, and polyvinylpyr 
rolidone, polyethyleneglycol, ethylcellulose and waxes. 
Typical lubricants for use in these dosage forms can 
include, without limitation, sodium benzoate, sodium 
acetate, sodium chloride, leucine and polyethyleneg 
lycol. Suitable disintegrators can include, without limi 
tation, starch, methylcellulose, agar, bentonite, cellu 
lose and wood products, alginic acid, guar gum, citrus 
pulp, carboxymethylcellulose and sodium lauryl sulfate. 
If desired, a conventionally pharmaceutically accept 
able dye can be incorporated into the dosage unit form, 
i.e., any of the standard FD&C dyes. 
Any skilled artisan can prepare these oral dosage 
forms by simply referring to the oral dosage form pre 
paratory procedure outlined in “REMINGTON’S 
PHARMACEUTICAL SCIENCE ,” Fourteenth Edi 
tion (1970), pp. 1659-1698, inclusive. 
The dose administered, whether a single dose or a 
daily dose will, of course, vary with the needs of the 
individual being treated. However, the dosage adminis 
tered is not subject to de?nite bounds, but it will usually 
be an effective therapeutic amount, or the equivalent on 
a molar basis of the pharmacologically-active form 
produced upon the metabolic release of the active drug 
(2-acetoxybenzoic acid) to achieve its desired pharma 
cological or physiological effect. 
Although the present invention has been adequately 
described in the foregoing speci?cation and examples 
included therein, it is apparent that various changes 
and/or modi?cations can be made thereto by the skilled 
artisan without departing from the spirit and scope 
thereof. Such changes and/or modi?cations are prop 
erly, equitably and intended to be within the full range 
of equivalence of the following claims. 
What is claimed is: 
1. The compound l-O-(2’-acetoxy)benzoyl-a-D-2 
deoxyglucopyranose. 
2. A method for inducing an analgesic, antipyretic, 
antirheumatic or anti-in?ammatory response in a warm 
blooded animal which comprises orally administering 
thereto an effective amount of l-O-(2'-acetoxy)benzoyl 
a-D-2-deoxyglucopyranose. 
3. A pharmaceutical composition of matter adapted 
for oral administration comprising an effective analge 
sic, antipyretic, antirheumatic or anti-in?ammatory 
amount of l-O-(2’-acetoxy)benzoyl-a-D-2-deoxy 
glucopyranose and a pharmaceutically acceptable inert 
carrier. 
4. The method as de?ned by claim 2, for inducing an 
analgesic response. 
4,242,330 . 
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s. The method as de?ned by claim 2, for inducing an 11- The °°mP°Slll°" of 91mm 3, comp?smg a" mil-"r 
?ammatory amount of said glucopyranose. 
annpyrenc response‘ 12. A compound having the structural formula: 
6. The method as defined by claim 2, for inducing an 
antirheumatic response. 5 
7. The method as de?ned by claim 2, for inducing an E_o R0 OR 
anti-in?ammatory response. 
8. The composition of claim 3, comprising an analge- ‘ o 
sic amount of said glucopyranose. ‘0 O-?"CH3 CHZOR 
9. The composition of claim 3, comprising an antipy- " 
retic amount of said glucopyranose. 
10. The composition of claim 3, comprising an anti 
rheumatic amount of said glucopyranose. 1 
wherein R is selected from the group consisting of ben 
zyl, p-methoxybenzyl and tert-butyl. 
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